Sun maintained it would retain the best of both organisations to build a global pharma company.
It is likely that the import duty on input materials would be maintained at the current levels. However many finished products with lower import duty compared to duty on input materials may be increased.
The top gainers on the Sensex were Cipla, Bharti Airtel, Maruti Suzuki, Hero Moto & Sesa Sterlite.
Pharmaceutical companies in the country offering any financial incentive to doctors to prescribe particular drugs may become a thing of the past if the drug manufacturers decide to follow the strict code of conduct being implemented by a US industry trade group.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
.jpg)
The Drug (Prices Control) Order implemented in May last year brought into its purview 652 packs of 348 formulations.
Imports too tumbled by 58.65 per cent to $17.12 billion in April from $41.4 billion in the same month last year, according to the data by the commerce and industry ministry.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
Sun-Ranbaxy are keen to complete the merger process.
In a communication to chief secretaries and director generals of police of all states, the ministry asked them to take action to allay apprehensions and maintain peace and tranquillity, and inform people about the availability of food, medicine and other essential commodities.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Indian markets ended on a lower note after the stimulus announced by the European Central Bank (ECB) failed to meet expectation.
Telangana chief minister K Chandrasekhar Rao on Wednesday announced the establishment of a massive industrial park dedicated to pharmaceutical manufacturing activities.
IT and IT-enabled services will be allowed to operate with essential minimum staff only while the rest would work from home.
This will boost availability of these items as well as make them cheaper, it said, adding that Modi also directed the revenue department to ensure seamless and quick custom clearance of such equipment.
It is a Budget with a strong emphasis on agriculture, education, healthcare and infrastructure.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
'I never thought the European audience will love this film, but we had over 2,000 people at the screening.'
The overall confirmed cases on the mainland have reached 81,518 as of Monday, which included 3,305 people who died of the of disease.
Inspections only in domestic authorities' presence, visiting US drug regulator told
Representatives from four states including Maharashtra and Karnataka will also be members of the panel.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
The government is considering setting up air freight stations to enable direct movement of vaccines from pharmaceutical factories to the aircraft.
In 2019 investors backed some of the major online healthcare and pharmacy retailers, with PharmEasy leading the deal list. The firm raised funds through the year to bring in around $220 million and the round is yet to be concluded, according to Venture Intelligence data.
Indian companies had invested $7.34 billion.
The government on Tuesday said it is considering forming a venture capital fund of Rs 2,000 crore (Rs 20 billion) to promote research and development (R&D) in the pharmaceutical sector.
Drug Controller General G N Singh said the regulator is addressing all the pending issues to liberate the pharma sector and to simplify export regulations which will be reflected in the forthcoming policy.
While salary growth may range from a marginally positive to stagnant or even negative, the increment for some of the "super-specialised" profiles can go beyond 15%.
In February, Indian companies had invested $1.66 billion overseas.
The government regulates prices of all other medicines.
After a long wait, the Shapoorji Pallonji Group has closed the sale process of its consumer durables business under the Eureka Forbes label by picking the American private equity fund Advent International's Rs 4,400-crore offer for a 72 per cent stake. The sale process, which began in November 2019, will help the over 156-year-old SP Group pair the debt pile and sharpen the focus on the flagship construction and engineering business under Afcons. The valuation of Rs 4,400 crore for a 72.56 per cent stake is is at an enterprise level and subject to closing adjustments and also includes an open offer for the remaining stake after the demerger and listing of Eureka Forbes, the SP group said in a statement on Sunday.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Despite the $11.7 billion raised by Reliance Industries Ltd (RIL) through stake sales, venture investments in 2020 have declined by a fifth to $28.9 billion till September, consultancy firm EY said in a report on Thursday. Since mid-March, coronavirus infections started getting reported in the country, which has now become the second highest globally in terms of numbers. The lockdowns severely dented economic activity, leading to a 23.9 per cent contraction in the gross domestic product (GDP) for the April-June period and expectations of a 9.5 per cent contraction by the Reserve Bank of India (RBI) for 2020-21.
The prime minister is likely to talk about its possible extension.
Cadient clients are spread across pharmaceutical, biotechnology, consumer health and medical device industries.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
Without naming the entity, he said some players are at a pre-clinical stage and may reach the clinical stage by October. Responding to a question on absence of a vaccine currently and the prospects in the next few months as the lockdown eases, VijayRaghvan emphasised on aggressive rapid testing and tracking.
Fortune seekers in the Indian pharmaceutical space will find this irresistible. In less than 24 months, 26 blockbuster medicines, worth over $69 billion (about Rs 3,10,000 crore) -- or thrice the size of the domestic industry -- are going off-patent in the world's largest drug market, the United States.
